blisibimod | |
---|---|
Trade Name | |
Orphan Indication | Patients with immunoglobulin A nephropathy |
USA Market Approval | USA |
USA Designation Date | 2017-08-07 00:00:00 |
Sponsor | Anthera Pharmaceuticals, Inc.;25801 Industrial Boulevard, Suite B;Hayward, California, 94545 |